DOCETAXEL\DOCETAXEL ANHYDROUS: 3,830 Adverse Event Reports & Safety Profile
Prostate Health & Male Vitality — Naturally
ProstaVive: better flow, better sleep, better energy. 180-day guarantee.
3,830
Total FAERS Reports
499 (13.0%)
Deaths Reported
1,438
Hospitalizations
3,830
As Primary/Secondary Suspect
273
Life-Threatening
90
Disabilities
First Report: 20010601 · Latest Report: 20240918
What Are the Most Common DOCETAXEL\DOCETAXEL ANHYDROUS Side Effects?
#1 Most Reported
Diarrhoea
409 reports (10.7%)
#2 Most Reported
Myelosuppression
404 reports (10.5%)
#3 Most Reported
Disease progression
289 reports (7.5%)
All DOCETAXEL\DOCETAXEL ANHYDROUS Side Effects by Frequency
| Side Effect | Reports | % of Total | Deaths | Hosp. |
|---|---|---|---|---|
| Diarrhoea | 409 | 10.7% | 129 | 195 |
| Myelosuppression | 404 | 10.6% | 10 | 246 |
| Disease progression | 289 | 7.6% | 65 | 46 |
| Off label use | 281 | 7.3% | 51 | 115 |
| Nausea | 279 | 7.3% | 92 | 104 |
| Neutropenia | 250 | 6.5% | 46 | 85 |
| Fatigue | 236 | 6.2% | 107 | 73 |
| Pyrexia | 221 | 5.8% | 75 | 109 |
| Vomiting | 216 | 5.6% | 79 | 93 |
| Asthenia | 190 | 5.0% | 71 | 59 |
| Anaemia | 188 | 4.9% | 29 | 79 |
| Drug ineffective | 184 | 4.8% | 39 | 42 |
| Decreased appetite | 172 | 4.5% | 74 | 53 |
| Dyspnoea | 162 | 4.2% | 82 | 39 |
| Febrile neutropenia | 155 | 4.1% | 40 | 91 |
| Alopecia | 148 | 3.9% | 37 | 30 |
| White blood cell count decreased | 146 | 3.8% | 7 | 58 |
| Neuropathy peripheral | 135 | 3.5% | 27 | 38 |
| Product use in unapproved indication | 134 | 3.5% | 8 | 88 |
| Malignant neoplasm progression | 126 | 3.3% | 39 | 16 |
Who Reports DOCETAXEL\DOCETAXEL ANHYDROUS Side Effects? Age & Gender Data
Gender: 62.1% female, 37.9% male. Average age: 58.5 years. Most reports from: CN. View detailed demographics →
Is DOCETAXEL\DOCETAXEL ANHYDROUS Getting Safer? Reports by Year
| Year | Reports | Deaths | Hosp. |
|---|---|---|---|
| 2001 | 2 | 0 | 0 |
| 2007 | 1 | 0 | 0 |
| 2008 | 4 | 0 | 4 |
| 2009 | 5 | 0 | 0 |
| 2010 | 1 | 0 | 1 |
| 2011 | 15 | 2 | 2 |
| 2012 | 20 | 4 | 6 |
| 2013 | 16 | 0 | 7 |
| 2014 | 28 | 4 | 6 |
| 2015 | 45 | 19 | 20 |
| 2016 | 43 | 9 | 16 |
| 2017 | 48 | 10 | 25 |
| 2018 | 73 | 4 | 25 |
| 2019 | 66 | 6 | 28 |
| 2020 | 112 | 13 | 33 |
| 2021 | 136 | 17 | 45 |
| 2022 | 137 | 28 | 70 |
| 2023 | 582 | 67 | 301 |
| 2024 | 829 | 26 | 454 |
What Is DOCETAXEL\DOCETAXEL ANHYDROUS Used For?
| Indication | Reports |
|---|---|
| Breast cancer | 791 |
| Product used for unknown indication | 388 |
| Her2 positive breast cancer | 216 |
| Breast cancer metastatic | 200 |
| Prostate cancer | 182 |
| Breast cancer female | 159 |
| Invasive ductal breast carcinoma | 149 |
| Prostate cancer metastatic | 116 |
| Lung adenocarcinoma | 114 |
| Chemotherapy | 107 |
DOCETAXEL\DOCETAXEL ANHYDROUS vs Alternatives: Which Is Safer?
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCONEXENT
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCONEXENT\ICOSAPENT
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCONEXENT\ICOSAPENT\PHOSPHATIDYL SERINE
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCOSANOL
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCUSATE
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCUSATE\SENNOSIDES
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOCUSATE\SENNOSIDES A AND B
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOFETILIDE
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOLUTEGRAVIR
DOCETAXEL\DOCETAXEL ANHYDROUS vs DOLUTEGRAVIR\LAMIVUDINE
Official FDA Label for DOCETAXEL\DOCETAXEL ANHYDROUS
Official prescribing information from the FDA-approved drug label.